Viridian Therapeutics Terminates Material Definitive Agreement
Ticker: VRDN · Form: 8-K · Filed: Mar 4, 2025 · CIK: 1590750
Sentiment: neutral
Topics: agreement-termination, material-definitive-agreement
TL;DR
Viridian Therapeutics just terminated a big deal. What's next?
AI Summary
Viridian Therapeutics, Inc. announced on March 3, 2025, the termination of a material definitive agreement. The company, formerly known as Miragen Therapeutics, Inc., is incorporated in Delaware and headquartered in Waltham, MA.
Why It Matters
The termination of a material definitive agreement can signal a shift in the company's strategic partnerships or operational plans, potentially impacting future business development and financial performance.
Risk Assessment
Risk Level: medium — Termination of a material definitive agreement can introduce uncertainty regarding future business operations and financial stability.
Key Players & Entities
- Viridian Therapeutics, Inc. (company) — Registrant
- March 3, 2025 (date) — Date of earliest event reported
- Miragen Therapeutics, Inc. (company) — Former company name
- Delaware (jurisdiction) — State of incorporation
- Waltham, MA (location) — Business address
FAQ
What was the material definitive agreement that was terminated?
The filing does not specify the details of the material definitive agreement that was terminated.
What is the reason for the termination of the agreement?
The filing does not provide the reason for the termination of the material definitive agreement.
When was the agreement entered into?
The filing does not state when the terminated agreement was originally entered into.
Will this termination have a significant financial impact on Viridian Therapeutics?
The filing does not disclose the potential financial impact of the agreement's termination.
Are there any other agreements that are affected by this termination?
The filing does not mention any other agreements affected by this termination.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 4, 2025 regarding Viridian Therapeutics, Inc.\DE (VRDN).